Our multi-omics approach, including transcriptomics and small RNA sequencing, and Raman spectroscopy, provided convergent evidence of the CXG solution’s efficacy in targeting GBM via key molecular axes, particularly the hsa-miR-10a-5p/BCL2L11/BCL2 and CX/SREBF1/E2F1/hsa-miR-29a-3p feed-forward loop. The gene discussed is BCL2; the disease is glioblastoma.